NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$492.86

-3.58 (-0.72 %)

(As of 01/22/2021 04:42 PM ET)

Add

Compare

Today's Range

$490.00

Now: $492.86▼

$498.98

50-Day Range

$449.88

MA: $484.95▼

$513.20

52-Week Range

$168.65

Now: $492.86▼

$516.86

Volume329,387 shs

Average Volume380,635 shs

Market Capitalization$42.04 billion

P/E Ratio85.86

Dividend YieldN/A

Beta0.88

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

MarketRank^™

Overall MarketRank^™

1.46 out of 5 stars

Medical Sector

470th out of 1,922 stocks

Diagnostic Substances Industry

8th out of 32 stocks

1.5 Analyst's Opinion

Consensus Rating
IDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $395.67, IDEXX Laboratories has a forecasted downside of 20.2% from its current price of $495.92.
Amount of Analyst Coverage
IDEXX Laboratories has received no research coverage in the past 90 days.

2.9 Community Rank

Outperform Votes
IDEXX Laboratories has received 478 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IDEXX Laboratories has received 341 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IDEXX Laboratories has received 58.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote “Outperform” if you believe IDXX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IDEXX Laboratories does not currently pay a dividend.
Dividend Growth
IDEXX Laboratories does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,699,069.00 in company stock.
Percentage Held by Insiders
Only 2.53% of the stock of IDEXX Laboratories is held by insiders.
Percentage Held by Institutions
85.06% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for IDEXX Laboratories are expected to grow by 12.72% in the coming year, from $6.13 to $6.91 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEXX Laboratories is 86.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.65.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEXX Laboratories is 86.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 36.00.
Price to Earnings Growth Ratio
IDEXX Laboratories has a PEG Ratio of 4.55. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IDEXX Laboratories has a P/B Ratio of 239.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:IDXX

Previous Symbol

CUSIP45168D10

CIK874716

Webwww.idexx.com

Phone207-556-0300

Employees9,200

Debt

Debt-to-Equity Ratio1.93

Current Ratio1.65

Quick Ratio1.24

Price-To-Earnings

Trailing P/E Ratio85.86

Forward P/E Ratio80.40

P/E Growth4.55

Sales & Book Value

Annual Sales$2.41 billion

Price / Sales17.47

Cash Flow$5.96 per share

Price / Cash Flow82.76

Book Value$2.07 per share

Price / Book238.10

Profitability

EPS (Most Recent Fiscal Year)$4.89

Net Income$427.72 million

Net Margins19.20%

Return on Equity198.91%

Return on Assets25.75%

Miscellaneous

Outstanding Shares85,300,000

Market Cap$42.04 billion

Next Earnings Date2/2/2021 (Confirmed)

OptionableOptionable

$492.86

-3.58 (-0.72 %)

(As of 01/22/2021 04:42 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

How has IDEXX Laboratories' stock been impacted by Coronavirus?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDXX stock has increased by 100.7% and is now trading at $492.86.
View which stocks have been most impacted by COVID-19.

Is IDEXX Laboratories a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as IDEXX Laboratories' CEO?

1,448 employees have rated IDEXX Laboratories CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among IDEXX Laboratories' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for IDEXX Laboratories.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings data on Thursday, October, 29th. The company reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.27. The firm had revenue of $721.79 million for the quarter, compared to analysts' expectations of $672.48 million. IDEXX Laboratories had a net margin of 19.20% and a return on equity of 198.91%. The company's revenue was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.24 EPS.
View IDEXX Laboratories' earnings history.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has authorized a share repurchase plan on Wednesday, February 12th 2020, which permits the company to buyback 5,000,000 shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued.

What price target have analysts set for IDXX?

3 equities research analysts have issued 12-month price objectives for IDEXX Laboratories' stock. Their forecasts range from $375.00 to $422.00. On average, they expect IDEXX Laboratories' stock price to reach $395.67 in the next twelve months. This suggests that the stock has a possible downside of 19.7%.
View analysts' price targets for IDEXX Laboratories or view Wall Street analyst' top-rated stocks.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 684,500 shares, a drop of 16.8% from the December 15th total of 823,100 shares. Based on an average trading volume of 400,800 shares, the short-interest ratio is currently 1.7 days. Currently, 0.8% of the shares of the company are sold short.
View IDEXX Laboratories' Short Interest.

Who are some of IDEXX Laboratories' key competitors?

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all of IDXX's competitors.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:

Mr. Jonathan J. Mazelsky, Pres, CEO & Director (Age 60, Pay $1.62M)
Ms. Sharon E. Underberg, Exec. VP, CFO & Treasurer (Age 60, Pay $809.42k)
Ms. Kathy V. Turner, Chief Marketing Officer & Corp. VP (Age 57, Pay $1.95M)
Mr. Jonathan W. Ayers, Sr. Advisor & Director (Age 65, Pay $3.2M)
Mr. Michael J. Lane, Exec. VP and GM of Reference Laboratories & Information Technology (Age 53, Pay $724.02k)
Mr. John Hart, Corp. VP of Worldwide Operations
Mr. Jeffery D. Chadbourne, Sr. Director of Accounting & Financial Reporting (Age 45)
Mr. Jeffrey Thomas, Corp. VP & Chief Technology Officer
Mr. Ken Grady, Corp. VP & Chief Information Officer
Ms. Kerry Bennett, VP of Investor Relations

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.25%), Welch & Forbes LLC (0.21%), Manning & Napier Group LLC (0.19%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), Ardevora Asset Management LLP (0.12%) and Harvey Investment Co. LLC (0.09%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Baldwin Brothers Inc. MA, Pacer Advisors Inc., Gateway Investment Advisers LLC, Welch & Forbes LLC, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, Cacti Asset Management LLC, and First Hawaiian Bank. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, and Rebecca M Henderson.
View insider buying and selling activity for IDEXX Laboratories or view top insider-selling stocks.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Frontier Capital Management Co. LLC, DNB Asset Management AS, Louisiana State Employees Retirement System, LGT Capital Partners LTD., Kestra Advisory Services LLC, Crossmark Global Holdings Inc., and Eastern Bank.
View insider buying and selling activity for IDEXX Laboratories or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $492.86.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $42.04 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here